Sign in
Taking people in United StatesNo phase

Collecting spinal fluid samples from people with metastatic breast cancer

Collects spinal fluid and other samples to study spread to the brain.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Status
Recruiting
People taking part
139 people, planned
Starts
18 Nov 2026
Expected to end
1 Jul 2034
Type of study
Observational, 4 groups
Treatments tested
  • Arm 1
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with HER2-positive or triple negative breast cancer that has spread to other parts of the body but not to the brain. Samples of spinal fluid, blood and saliva are collected for research.

Age
18 years and older
Sex
Women
Disease stage
HER2-positive breast cancer or triple negative breast cancer, confirmed by pathology, with a history of metastatic disease and no brain metastases.
Biomarker or test result
HER2-positive or triple negative breast cancer.

Main reasons for not taking part

  • Brain metastases or leptomeningeal disease, now or in the past
  • Previous invasive cancer, except surgically removed local skin cancer
  • Pregnancy
  • Cannot have a lumbar puncture or brain MRI
  • Kidney function below the limits set in the record

The registry criteria, word for word

Show all 9 criteriaShow less

Who cannot take part

  • Prior history or current MRI-detected brain metastasis or leptomeningeal disease
  • Previous history of any invasive malignancies, except for surgically resected local cutaneous malignancies
  • Pregnancy

Other criteria

  • INCLUSION CRITERIA:
  • Pathology documentation of histologically confirmed HER2+ BC or TNBC with a history of metastatic disease
  • Participants must be able to undergo lumbar puncture (LP) and brain MRI
  • Women age >= 18 years
  • Adequate organ function as defined below:; Creatinine <=1.5 x institutional upper limit of normal (ULN); OR; --Calculated Creatinine clearance >=40 mL/min/1.73 m2 for individuals with creatinine levels above institutional ULN (using either Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation)
  • Participants must be able to understand and willing to sign a written informed consent document

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 120 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: National Cancer Institute Referral OfficeTaking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal. Researchers want to know if tumor DNA found in spinal fluid, blood, or tumor tissue can help predict when the cancer will spread to the brain. They want to collect these fluid and tissue samples for research.

Objective:

To collect spinal fluid and other samples from people with breast cancer that has spread to other parts of the body.

Eligibility:

People aged 18 years and older with HER2-positive or triple negative breast cancer. The cancer must have spread to other parts of the body but not to the brain.

Design:

Participants will be screened. They will have blood tests to assess kidney function. They will have an imaging scan of the brain.

Participants will come to the NIH clinic to have their samples collected:

* Spinal fluid. A thin needle will be inserted into the lower back to draw out a sample of fluid from the space around the spinal cord. A physical exam and blood tests will be done to make sure it is safe for participants to have this procedure. * Blood. * Saliva or cheek swabs. They will rub a cotton swab inside of their mouth. * Tumor samples. If participants have had samples of tumor tissue (biopsies) collected in the past, leftover tissue may be used for this study.

Participants will be contacted for follow-up every 6 months for 3 years. They may return once a year to provide further samples.

The 4 groups in the trial

  • Cohort 1

    Participants with metastatic triple negative breast cancer (mTNBC) without a history or active radiographically detectable CNS disease who underwent at least one systemic therapy

    Treatment: Arm 1

  • Cohort 2

    Participants with metastatic HER2+ BC without a history or active radiographically detectable CNS disease who underwent at least one systemic therapy

    Treatment: Arm 1

  • Cohort 3

    Participants with newly diagnosed mTNBC without a history or active radiographically detectable CNS disease and without prior systemic therapies

    Treatment: Arm 1

  • Cohort 4

    Participants with newly diagnosed metastatic HER2+ BC without a history or active radiographically detectable CNS disease and without prior systemic therapies

    Treatment: Arm 1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sample Collection Study to Analyze Cerebral Spinal Fluid as a Biomarker for Brain Metastasis in Metastatic Breast Cancer
Plain-language title
Collecting spinal fluid samples from people with metastatic breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07619534, who can take part
Record updated
13 November 2026